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ABBREVIATIONS 
APCs  Antigen presenting cells 
BSA  Bovine serum albumin 
DCs  Dendritic cells 
DoE  Design of experiment 
LN  Lymph node 
NPs  Nanoparticles 
NCMPs Nanocomposite microparticles 
PGA-co-PDL poly(glycerol adipate-co-ω-pentadecalactone) 
PLA  polylactide or poly-L-lactic acid 
PLGA  poly lactic-co-glycolic-acid 
PVA  polyvinyl alcohol 
SD  Spray-drying 
  
1. Introduction 
Vaccination refers to induction of an immune response using antigens coupled with adjuvants 
for generating a protective immunity against plausible future infections [1,2]. Traditional 
vaccines are often administered via the parenteral route requiring infrastructure such as cold-
chain, sterilized water for reconstitution of dry powder vaccines and trained medical personnel. 
Lack of these facilities in low and middle income countries (LMIC) is leading to many eligible 
children and adults not getting vaccinated [3]. Moreover, the majority of the potential vaccines 
in development employ purified subunits or recombinant proteins that are often poorly 
immunogenic thus needing adjuvants and effective delivery systems to generate an optimal 
immune response [1,2]. To address these issues, particulate delivery systems and non-invasive 
routes of delivery are being investigated. The pulmonary route has gained significant attention 
for delivery of vaccines as it is one of the main entry portals for pathogens, and can address 
some of the challenges such as invasiveness, cold-chain requirement, and stability of the 
antigen by delivering the antigen as a dry powder [3]. 
Biodegradable polymeric nanoparticles (NPs) have gained significant attention and are largely 
being explored as delivery vehicles for delivery of peptides, proteins, antigens, DNA etc. [3–
5]. These polymers offer controlled or sustained drug release, biocompatibility with 
surrounding cells and tissues, degrade into low molecular weight non-toxic products and act as 
adjuvants helping in generating cellular and humoral immune responses [1,3,6]. In this current 
investigation we aim to use poly(glycerol adipate-co-ω-pentadecalactone), PGA-co-PDL, a 
biodegradable polyester polymer, that has extensively been studied by our group for delivery 
of both small molecule and model drugs (dexamethasone phosphate, ibuprofen, sodium 
fluorescein), and large molecule drugs (α-chymotrypsin, DNase I) [7–11]. 
In these biodegradable polymeric nanoparticulate formulations, the vaccine antigens (i.e. 
proteins, peptides etc.) are either adsorbed onto the surface or encapsulated within the particles 
[3]. Encapsulated antigens are protected by polymeric nanoparticles and their release can be 
modified by tailoring the properties of the polymers. Adsorbed antigen, however, offers 
enhanced stability and activity over the encapsulated antigen by avoiding contact with organic 
solvents employed during particle preparation steps [12–14]. 
Recent strategies for effective vaccine delivery have been to target the dendritic cells (DCs), 
the true professional antigen presenting cells (APCs) [15]. DCs have the exceptional ability to 
internalize, and in lymph nodes (LNs) they process and present antigens through major 
histocompatibility complex (MHC) class I and II pathways thereby activating naïve T-cells 
resulting in induction of a strong immune response [3,15,16]. A study conducted by Manolova 
et al indicates the importance of particle size in determining the uptake by DCs, where it was 
shown that upon intracutaneous injection of polystyrene beads of varying sizes, large particles 
(500–2000 nm) associated with DCs from the site of injection whereas small particles (20–200 
nm) drained freely to the LNs and were present in LN resident DCs [16]. In addition, Kim et 
al have also shown that uptake of 200 nm sized NPs by bone marrow DCs to be more than that 
of 30 nm sized NPs [17]. Furthermore, Foged et al has shown that particle size of 500 nm or 
below were preferred and have shown fast and efficient up take by human DCs derived from 
blood [18]. The above literature suggests that smaller particles of 200 to 500 nm could 
effectively be up taken by DCs and thus generates a stronger immune response compared to 
vaccine alone. However, these studies cannot be directly compared to lung DCs but owing to 
the lack of information on the effect of NP size on uptake by lung DCs the same can be 
assumed. 
In this study, the Taguchi L18 orthogonal array design of experiment (DoE) was used to 
optimize the formulation parameters to achieve NPs (~150 nm) for targeting the lung DCs. The 
literature suggests that factors such as molecular weight (MW) of the polymer, organic solvent, 
aqueous phase, sonication time and stirrer speed have an influence on the size of the resultant 
NPs [19–21] and these were evaluated using the experimental design. 
As a dry powder, the nanosized particles cannot be directly used for inhalation as their size is 
too small and it is expected that majority of the inhaled dose will be exhaled depositing very 
minimal doses in the lung [22]. Thus, these nanoparticles are formulated into nanocomposite 
microparticles (NCMPs) using additives such as lactose [22], L-leucine [23,24], trehalose[25], 
mannitol [25] by various manufacturing techniques such as freeze drying, spray drying, spray-
freeze drying or supercritical fluid technologies [3,26]. The NCMPs in the size range of 1 to 5 
μm in diameter are reported to be deposited in the respirable airways and periphery of the lung 
[27]. The additives used to form NCMPs dissolve upon encountering the respiratory 
environment thereby releasing the NPs [28]. 
In this project, we aim to produce PGA-co-PDL NPs of optimum size to be effectively taken 
up by the DCs, surface adsorb a model protein, bovine serum albumin (BSA) and formulate 
into nanocomposite microparticles (NCMPs) using L-leucine as a carrier for delivery via dry 
powder inhalation. 
2. Materials and Methods 
2.1. Materials 
Dichloromethane (DCM) was purchased from BDH, laboratory supplies, UK. Novozyme 435 
(a lipase from Candida antartica immobilized on a microporous acrylic resin) was purchased 
from Biocatalytics, USA. Acetonitrile (HPLC grade), albumin tagged with fluorescein 
isothiocyanate (FITC-BSA), bovine serum albumin (BSA, MW 67 KDa), phosphate buffered 
saline (PBS, pH 7.4) tablets, poly(vinyl alcohol) (PVA, MW 9–10 KDa, 80%), trifluoroacetic 
acid (TFA, HPLC grade), RPMI-1640 medium with L-glutamine and NaHCO3, thiazoly blue 
tetrazolium bromide (MTT), tween 80® and ω-pentadecalactone were obtained from Sigma-
Aldrich, UK. L-leucine (L-leu) was purchased from BioUltra, Sigma, UK. 75 cm2/tissue culture 
flasks with vented cap, 96-well flat bottom plates, acetone, antibiotic/ antimycotic solution 
(100X), dimethyl sulfoxide (DMSO) were purchased from Fisher Scientific, UK. 
Divinyladipate was obtained from Fluorochem, UK. Fetal calf serum (FCS) heat inactivated 
was purchased from Biosera UK. poly(glycerol adipate-co-ω-pentadecalactone) (PGA-co-
PDL, MW of 14.7, 24.0 KDa was synthesized in our laboratory at LJMU and micro BCA™ 
protein assay kit was purchased from Thermo Scientific, UK. A549 cell line was purchased 
from ATCC. 16HBE14o- cells were obtained from Dr Dieter Gruenert from the California 
Pacific Medical Center, University of California San Francisco, USA. 
2.2. Polymer Synthesis 
The PGA-co-PDL polymer of MW of 14.7, 24.0 KDa was synthesized in our laboratory via 
enzyme catalyzed co-polymerization of three monomers as described by Thompson et al. [29]. 
The synthesized linear polyester was characterized by gel permeation chromatography, GPC 
(Viscotek TDA Model 300 using OmniSEC3 operating software), pre-calibrated with 
polystyrene standards (polystyrene standards kit, Supelco, USA), and 1H-NMR spectroscopy 
(Bruker AVANCE 300 MHz, Inverse probe with B-ACS 60, Auto sampler with gradient 
chemming) as described by Thompson et al. [29]. 
2.3. Preparation of Nanoparticles 
The PGA-co-PDL NPs were fabricated using a modified oil-in-water (o/w) single emulsion 
solvent evaporation method [30]. Briefly, 200 mg PGA-co-PDL polymer (MW 14.7 KDa) (and 
Nile Red, NR 0.5 mg for characterization of protein adsorption onto the surface of PGA-co-
PDL via confocal microscopy) was dissolved in 2 ml DCM and probe sonicated (20 microns 
amplitude) upon addition to 5 ml of 10% w/v poly(vinyl alcohol) (PVA) (1st aqueous solution) 
for 2 min to obtain an emulsion. This whole process was performed using ice. This was 
immediately added drop wise to 20 ml of 2nd aqueous solution (0.75% w/v PVA) under 
magnetic stirring at a speed of 500 RPM. The whole mixture was left stirring at room 
temperature for 3 h to facilitate the evaporation of DCM. The particle size, PDI and zeta-
potential were then characterised as mentioned in section 2.6. The NP suspensions were 
collected by centrifugation (78,000g, 40 min, 4°C) and surface adsorbed with protein as 
indicated in section 2.54.  
2.4. Taguchi Design of Experiment (DoE) 
In order to evaluate the influence of formulation parameters and minimize the number of 
experiments, Taguchi DoE being appropriate to study large number of factors, was employed 
through Minitab® 16 Statistical Software. Seven factors, namely, polymer MW, organic 
solvent, internal aqueous phase concentration and volume, sonication time, stirrer speed and 
external aqueous phase concentration were evaluated by constructing and using L18 orthogonal 
array design with 1 factor, MW, at 2 levels and remaining 6 factors at 3 levels (Table I). 
The design was applied to identify the significant factors that would affect the size of PGA-co-
PDL NPs. Optimum conditions were indicated by high signal-to-noise (S/N) ratios, where 
signal factor (S) is the outcome, the particle size, and noise factors (N) are parameters such as 
humidity, temperature, experience of the experimenter etc. A greater S/N ratio corresponds to 
minimum variance of the outcome, the particle size i.e. a better performance. In other words, 
the experimental parameter having the least variability is the optimum condition [31]. The 
optimization of size was carried out using the Taguchi’s ‘smaller-is-better’ criterion i.e. to get 
the outcome, the particle size, to an ideal target of zero or as small as possible. 
2.5. Protein Adsorption 
NP suspension (equivalent to 10 mg i.e. 1.25 ml of suspension) was centrifuged (78,000g, 40 
min, 4°C) and the resultant pellet was resuspended in vials containing 4 ml of BSA (or FITC-
BSA for characterization of protein adsorption onto the surface of PGA-co-PDL via confocal 
microscopy), for 1 h, at different ratios of 100: 4, 100: 10 and 100: 20 (NPs: BSA) 
corresponding to 100, 250 and 500 µg/ml BSA concentrations, respectively. The resulting 
suspension (for 100: 20) was left rotating for 30 min, 1, 2 and 24 h at 20 RPM on a HulaMixerTM 
Sample Mixer (Life Technologies, Invitrogen, UK). After respective time points, the protein 
adsorbed NP suspensions were centrifuged and the supernatant analysed for protein content 
using micro BCA protein assay kit. The amount of BSA adsorbed per milligram of NPs (n=3) 
was calculated using eq. 1: 
Adsorption (µg per mg of NPs)= (Initial protein conc-Supernatant protein conc)
Amount of NPs
 (1) 
The particle size and PDI were then characterised as mentioned in section 2.6. 
2.6. Nanoparticle Characterization 
Particle size, poly dispersity index (PDI, a number between 0 and 1 describing the homogeneity 
of the sample) and zeta-potential were measured by laser diffraction using a laser particle size 
analyser (Zetasizer Nano ZS, Malvern Instruments Ltd, UK). For NPs suspension, an aliquot 
of 100 µl of the NP suspension was diluted with 5 ml of deionized water and for NP suspensions 
with and without BSA adsorption, 2 mg of NPs were resuspended in 5 mL of deionized water, 
loaded into a cuvette and the measurements were recorded at 25°C (n=3). 
2.7. Nanocomposite Microparticles 
Spray-drying was employed to incorporate the NPs into nanocomposite microparticles 
(NCMPs) using L-leucine as a carrier, and at nanoparticles-to-carrier ratio of 1:1.5 w/w. Blank 
NPs, BSA-loaded NPs or FITC-BSA-loaded NR NPs were dispersed in 20 ml water with L-
leucine dissolved and spray-dried using a Büchi B-290 mini spray-dryer (Büchi Labortechnik, 
Flawil, Switzerland) with a nozzle atomizer, and nozzle orifice diameter of 0.7 mm. The spray-
drying was performed at a feed rate 10%, an atomizing air flow of 400 L/h, aspirator capacity 
of 100% and an inlet temperature of 100°C (outlet temperature approximately 45 - 47°C). The 
dry particles (PGA-co-PDL/L-leu NCMPs) were separated from the air stream using a high-
performance cyclone (Büchi Labortechnik), and the dry particles were collected and stored in 
desiccator until further use. 
2.8. Nanocomposite microparticles Characterization 
2.8.1. Yield 
The dry powder yield was determined as the difference in the weight of the sample vial before 
and after product collection. The weight difference was compared to the initial total dry mass 
and the yield in % (w/w) was calculated (n=3). 
2.8.2. Particle Size and Morphology 
To confirm the recovery of NPs from NCMPs with an appropriate size range for cellular uptake, 
particle size and PDI of NPs following re-dispersion of blank and loaded NCMPs in water were 
measured. The measurements were recorded as mentioned in section 2.6, where 5 mg of 
NCMPs were dispersed in 2 ml of deionized water then loaded into a cuvette and the 
measurements were recorded at 25°C (n=3).  
Spray dried PGA-co-PDL/L-Leu NCMPs samples were mounted on aluminium stubs (pin 
stubs, 13 mm) layered with a sticky conductive carbon tab and coated with palladium (10-15 
nm) using a sputter coater (EmiTech K 550X Gold Sputter Coater, 25 mA for 3 min). The 
particles were then visualized using scanning electron microscopy (FEI Quanta™ 200 ESEM, 
Holland). 
2.8.3. Confocal Laser Scanning Microscopy 
FITC-BSA-loaded NR NPs spray-dried into NCMPs were observed under confocal microscope 
to visualise the adsorption of BSA onto the NPs. Briefly, a Zeiss 510 Meta laser scanning 
microscope mounted on a Axiovert 200 M BP computer-controlled inverted microscope was 
used to obtain the confocal images. A few milligrams of spray-dried NCMPs were placed in a 
single well of 8-well chambered (Fisher Scientific, UK) and imaged by excitation at a 
wavelength of 488 nm (green channel for FITC-BSA), 543 nm (red channel for Nile Red NPs) 
and a Plan Neofluar 63×/0.30 numerical aperture (NA) objective lens. Image analysis was 
carried out using the Zeiss LSM software. 
2.8.3.2.8.4. Protein Quantification by HPLC 
An HPLC method was developed to quantify the amount of BSA present in NCMPs. The 
chromatographic conditions were as follows: HPLC system Agilent 1100 series (Santa Clara, 
CA, USA) equipped with a column (Aeris 3.6 μm C4 200A Wide Pore 4.6mm i.d. x 150 mm 
length), security cartridge of the same material (Phenomenex, UK) and software for data 
processing; mobile phase was composed of (A) 0.1% TFA in water and (B) 0.1% TFA in 
acetonitrile with a gradient flow of A/B from 80:20 to 35:65 in 25 min, post-time 6 min; flow 
rate of 0.8 ml/min; injection volume of 100 μl; run temperature 40°C; UV detection at 214 nm 
and BSA retention time of 14.4 min. BSA calibration curve was prepared by accurate dilution 
of a previously prepared stock solution (1 mg/ml) in HPLC water and PBS (pH 7.4) to obtain 
the following concentrations: 0.5, 1, 2.5, 5, 10, 25, 50, 100 and 200 μg/ml of BSA (n = 9, R2 = 
0.999). All solutions used in the process were filtered using 0.45 μm filters prior to use. Limit 
of Detection (LOD) in water – 1.98 μg/ml, PBS – 1.48 μg/ml and Limit of Quantification 
(LOQ) in water – 3.24 μg/ml, PBS – 3.20 μg/ml. 
2.8.4.2.8.5. In vitro Release Studies 
BSA adsorbed PGA-co-PDL/L-leu NCMPs (20 mg) were transferred into eppendorfs and 
dispersed in 2 ml of PBS, pH 7.4. The samples were incubated at 37C and left rotating for 48 
h at 20 RPM on a HulaMixerTM Sample Mixer (Life Technologies, Invitrogen, UK). At pre-
determined time intervals up to 48 h, the samples were centrifuged (accuSpin Micro 17, Fisher 
Scientific, UK) at 17,000g for 30 min and 1 ml of the supernatant removed and replaced with 
fresh medium. The supernatant was analysed using the HPLC method as mentioned above. 
Each experiment was repeated in triplicate and the result was the mean value of three different 
samples (n=3). The percentage cumulative BSA released was calculated using eq. 2: 
% Cumulative BSA released = Cumulative BSA released
BSA loaded
 × 100   (2) 
2.8.5.2.8.6. Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
The stability primary structure of BSA released from within the NCMPs after spray-drying was 
determined by SDS-PAGE. SDS-PAGE was performed on CVS10D omniPAGE vertical gel 
electrophoresis system (Geneflow Limited, UK) with 9% stacking gel prepared using ProtoGel 
stacking buffer (Geneflow Limited, UK) containing 0.4% of SDS. Protein molecular weight 
markers in the range 10–220 KDa (Geneflow Limited, UK) and BSA were used as control. The 
protein loading buffer blue (2X) (0.5M Tris-HCl (pH 6.8), 4.4% (w/v) SDS, 20% (v/v) 
Glycerol, 2% (v/v) 2- mercaptoethanol and bromphenol blue in distilled/deionised water) was 
added to the samples in 1:1 (v/v) buffer-to-sample ratio. After loading the samples (25 μl 
sample per well), the gel was run for approximately 2.5 h at a voltage of 100 V with Tris-
Glycine-SDS PAGE buffer (10X) (Geneflow Limited, UK) containing 0.25M Tris base, 1.92M 
glycine and 1% (w/v) SDS. The gel was stained with colloidal coomassie blue and then 
destained in distilled water overnight. An image of the gel was scanned on a gel scanner (GS-
700 Imaging Densitometer, Bio-Rad) equipped with Quantity One software. 
2.8.6.2.8.7. Circular Dichroism (CD) 
The secondary structure of standard BSA (control), BSA supernatant (after 1 h adsorption 
followed by centrifugation) and BSA released from NPs after 48 h was determined by 
measuring circular dichroism spectra. All CD experiments were performed using a J-815 
spectropolarimeter (Jasco, UK) at 20 °C as previously described [32]. Five scans per sample 
using a 10 mm path-length cell were performed over a wavelength range 260 to 180 nm at a 
data pitch of 0.5 nm, band width of 1 nm and a scan speed 50 nm min-1. Far-UV CD spectra 
were collated for standard BSA, supernatant BSA in HPLC grade water, BSA released in PBS 
for 48 h. For all spectra, the baseline acquired in the absence of sample was subtracted [33]. 
The secondary structure of the samples was estimated using using the CDSSTR method [34] 
from the DichroWeb server [34–36]. 
2.8.7.2.8.8. In vitro Aerosolization Studies 
The Next Generation Impactor (NGI) was employed to assess the aerosol performance of 
spray-dried NCMPs. The BSA adsorbed NCMPs were weighed (4 capsules each corresponding 
to 12.5 mg Spray-dried, SD, powder equivalent to 5 mg of NPs) and manually loaded into the 
hydroxypropyl methylcellulose, HPMC, capsule (size 3), and placed in a Cyclohaler® (Teva 
pharma). The samples were drawn through the induction port into the NGI using a pump 
(Copley Scientific, Nottingham, UK) operated at a flow rate of 60 L/min for 4 s. The plates 
were coated with 1% tween 80: acetone solution and samples collected using a known volume 
of distilled water, and left on a roller-shaker for 48 h for the BSA to be released from NCMPs. 
The samples were centrifuged using an ultracentrifuge (as mentioned in section 2.3) and the 
supernatants analysed using HPLC method as mentioned above to determine the amount of 
BSA deposited. The Fine Particle Fraction (FPF, %) was determined as the fraction of emitted 
dose deposited in the NGI with dae< 4.46 μm, the mass median aerodynamic diameter (MMAD) 
was calculated from log-probability analysis, and the fine particle dose (FPD) was expressed 
as the mass of drug deposited in the NGI dae < 4.46 μm (n=3). 
2.8.8.2.8.9. Cell Viability Study 
The in vitro cytotoxicity of the empty PGA-co-PDL/L-leu NCMPs was evaluated using the 
MTT assay. The adenocarcinomic human alveolar basal epithelial cell line, A549 (passage no. 
32) or 16HBE14o- cells (passage no. 32) were seeded in 100 μl (2.5 × 105 cells/ml) of RPMI-
1640 medium supplemented with 10% fetal calf serum/1% Antibiotic/Antimycotic solution 
(complete medium) in 96-well plates and placed in an incubator at 37°C for 24 h supplemented 
with 5% CO2. Then, 100 μl of freshly prepared NCMP dispersions in complete medium were 
added to the wells to an appropriate concentration (0 - 2.5 mg/ml) (n = 3), and 10% dimethyl 
sulfoxide (DMSO) as a positive control. The formulations were assayed for toxicity over 24 h 
of incubation, followed by the addition of 40 μl of a 5 mg/ml MTT solution in PBS to each 
well. After 2 h of incubation at 37°C, the culture medium was gently removed and replaced by 
100 μl of dimethyl sulfoxide in order to dissolve the formazan crystals. The absorbance of the 
solubilised dye, which correlates with the number of living cells, was measured at 570 nm 
using a plate reader (Molecular Devices, SpectraMAX 190). The percentage of viable cells in 
each well was calculated as the absorbance ratio between nanoparticle-treated and untreated 
control cells. 
2.9. Statistical Analysis 
All statistical analysis was performed using Minitab® 16 Statistical Software. One-way analysis 
of variance (ANOVA) using Minitab® 16 Statistical Software with the Tukey’s comparison 
was employed for comparing the formulations with each other. Statistically significant 
differences were assumed when p < 0.05. All values are expressed as their mean ± standard 
deviation. 
3. Results 
3.1. Polymer Synthesis 
The synthesized PGA-co-PDL co-polymer (monomer ratio, 1:1:1) was a white powder with a 
molecular weight of 14.7, 24.0 KDa for 6 h, 24 h as determined by the GPC. The integration 
pattern of the co-polymer was confirmed by 1H-NMR spectra, (δH CDCl3, 300 MHz): 1.34 (s, 
22 H, H-g), 1.65 (m, 8 H, H-e, e′, h), 2.32 (m, 6 H, H-d, d′, i), 4.05 (q)-4.18 (m) (6 H, H-a, b, 
c, f), 5.2 (s, H, H-j). 
3.2. Taguchi Design of Experiment (DoE) 
The Taguchi design was applied in this study to identify the significant factors that would 
influence the size of PGA-co-PDL NPs. Considering seven factors (1 factor at 2 levels and 6 
factors at 3 levels) to be investigated, non-usage of an experimental design would have resulted 
in 2*36 = 1458 individual experiments which would be an arduous task and inefficient. The 
Taguchi L18 orthogonal array design resulted in 18 runs to be performed to yield the optimum 
conditions for each factor in achieving the smallest PGA-co-PDL NP size. Table II illustrates 
the structure of the L18 orthogonal array, the corresponding results and S/N ratios. 
The results obtained from 18 runs indicated particle sizes ranging from 138.7±6.4 (run 3) to 
459.4±69.5 (run 11). Figure 1 shows the mean S/N graph of the particle size for each parameter 
level. The parameter with the largest range and corresponding rank (indicates the relative 
importance compared to other parameters) was considered as the critical factor affecting that 
particle size. 
Analysis of the particle sizes of 18 runs using the Taguchi’s ‘smaller-is-better’ criterion in 
Minitab® 16 Statistical Software, the optimum conditions inferred from the range, rank and the 
S/N response graph were A1B3C3D3E2F2G2. The optimum formulation made using these 
conditions yielded NPs with a size of 128.50±6.57 nm lower than the minimum size of 
138.7±6.4 nm obtained using run 3, PDI of 0.07±0.03 and zeta-potential of -10.2±3.75 mV. 
3.3. Protein Adsorption 
Figure 2a shows the amount of BSA adsorbed per mg of NPs for different concentrations of 
BSA loaded. The average adsorption of BSA, μg per mg of NPs, increased significantly from 
100: 4 (NP: BSA) loading concentration (4.75±0.39), 100: 10 (6.59±1.28) to 100: 20 
(10.23±1.87) (p < 0.05, ANOVA/Tukey’s comparison). 
Figure 2b shows the amount of BSA adsorbed in μg per mg of NPs at different time points for 
100: 20 (NP: BSA) loading concentration. The average adsorption increased significantly from 
30 min (1.84±0.82) to 1 h (10.23±1.87) (p < 0.05, ANOVA/Tukey’s comparison) with no 
significant difference beyond 1 h compared to that of 2 h (8.76±0.34) and 24 h (8.95±0.39) (p 
> 0.05, ANOVA/Tukey’s comparison) indicating maximum adsorption at 1 h. 
Table III lists the particle size and PDI of PGA-co-PDL NPs with and without BSA adsorption. 
As seen, there is a significant increase (p < 0.05, ANOVA/Tukey’s comparison) in size which 
is attributed to the adsorption of BSA onto NPs as confirmed using confocal microscopy 
(section 3.4.3).  
3.4. Nanocomposite Microparticles Characterization 
3.4.1. Yield 
A reasonable yield of spray drying, 40.36±1.80 % for the empty PGA-co-PDL NCMPs and 
42.35±3.17 % for the BSA adsorbed PGA-co-PDL/L-leu NCMPs was obtained. 
3.4.2. Particle Size and Morphology 
The size of NPs after recovery from spray-dried blank NCMPs in water was 210.03 ± 15.57 
nm and PDI 0.355 ± 0.067 and for that of BSA loaded NCMPs was 222.46 ± 2.17 nm and PDI 
0.36 ± 0.008, which is in the range of 200 to 500 nm for uptake by dendritic cells (DCs) [16-
18].  
The shape and surface texture of NCMPs were investigated using scanning electron 
microscopy (Fig. 3). Photomicrographs of NCMPs showed irregular and corrugated 
microparticles. 
3.4.3. Confocal Laser Scanning Microscopy 
CLSM was used to observe the interaction of BSA with NPs. The microscopic images in Fig. 
4a (split view) and 4b (orthogonal view) shows the spray-dried NCMPs containing the 
fluorescent nanoparticles (red, labelled using NR dye) adsorbed with FITC-BSA (green). The 
image shows that FITC-BSA was evidently only present where the NPs were present, 
indicating their association. Moreover, the increase in size observed after adsorption also 
confirms the adsorption of BSA onto PGA-co-PDL NPs (Table III). 
3.4.3.3.4.4. In vitro Release Studies  
In vitro release studies were performed on NCMPs and reported as cumulative percentage BSA 
released over time (Fig. 54). An initial burst release of 30.15±2.33 % (BSA) was observed 
followed by rapid continuous release that continued for up to 5 h, with BSA release of 
86.07±0.95 %. After this time period, a slow continuous release of BSA was observed with 
release of 95.15±1.08 % over 48 h, indicating an excellent release profile for the PGA-co-
PDL/L-leu NCMPs. 
3.4.4.3.4.5. Protein Stability (SDS-PAGE and CD) 
The primary structure of BSA released from the NCMPs was investigated using SDS-PAGE 
analysis. Figure 56 reveals identical bands for the standard BSA and desorbed BSA from 
NCMPs without any newly noticeable bands of high and low molecular BSA. 
The secondary structure analysis was performed using CD spectral data. Figure 7a and 7b 
shows the structure of standard BSA, BSA supernatant and BSA released. In Fig 7a, the CD 
spectra show minima at 221 - 222 and 209 – 210 nm and maximum at about 195 nm for both 
samples, which is characteristic of α-helical structure. Further structural analysis showed that 
the predominant structure of the peptide was helical displaying 51 and 62.5% helicity 
respectively (Table IV). Moreover, the experimental data obtained for the standard BSA are in 
good agreement with previous reports [37]. Figure 7b shows that BSA released displayed 
double minima at 208 and 222 nm and further spectra analysis indicated this sample adopted a 
reduced level helical conformation (circa 36% helical) (Table IV). Comparing the CD results 
of BSA released with that of standard BSA, the content of α-helix decreases by 15%, the β-
sheet content increases by 8.9%, the turns content increases by 1%, and the random coils’ 
content increases by 3% respectively. 
3.4.5.3.4.6. In vitro Aerosolization Studies 
The deposition data obtained from spray-dried formulations displayed a FPD of 112.87±33.64 
µg, FPF of 76.95±5.61 % and MMAD of 1.21±0.67 μm. This suggest that the BSA adsorbed 
PGA-co-PDL/L-leu NCMPs were capable of delivering efficient BSA to the lungs, and are 
expected to deposit the majority of the emitted dose to the bronchial-alveolar region of the 
lungs [3]. 
3.4.6.3.4.7. Cell Viability Study 
The non-adsorbed PGA-co-PDL NCMPs appear to be well tolerated by both the cell lines, with 
a cell viability of 87.01±14.11 % (A549 cell line) and 106.04±21.14 % (16HBE14o- cell line) 
(Fig. 68) at 1.25 mg/ml concentration after 24 h exposure indicating a good toxicity profile 
without any significant difference in cell viability between particle loadings. This provides an 
indication about the feasibility of using PGA-co-PDL polymers as safe carriers for pulmonary 
drug delivery. 
4. Discussion 
4.1. Nanoparticle Preparation and Characterization 
The PGA-co-PDL NPs were prepared using a modified oil-in-water (o/w) single emulsion 
solvent evaporation method [30]. The results of 18 runs, suggested by Taguchi’s L18 orthogonal 
array, resulted in NPs of size < 150 nm. However, this increases to about 200 - 300 nm after 
centrifugation and BSA adsorption. This according to the literature suggests free draining of 
NPs to the LN and also an effective uptake by DCs [16–18]. The effects of each factor are 
discussed in detail below: 
Factor D, PVA concentration (range = 3.17, rank = 1), is the most important factor affecting 
the particle size. The S/N ratios at three levels indicated that particle size almost linearly 
decreased with increase in surfactant concentration from 2.5 to 10% w/v (S/N ratio, r2 = 0.997). 
The particle size decreases because at lower concentrations there is inadequate amount of 
surfactant to cover all the surfaces of PGA-co-PDL NPs [38]. The uncovered NPs then tend to 
aggregate until a point where there is adequate amount of surfactant to cover the total surface 
area of the aggregated NPs, and form a stable system leading to larger particles. However, with 
an increase in surfactant concentration it was possible to efficiently cover all the surfaces of 
NPs thereby stabilizing the system avoiding aggregation and resulting in smaller PGA-co-PDL 
NPs [38]. This effect of decrease in particle size with an increase in surfactant concentration, 
PVA, was also observed by Mitra and Lin [39]. 
The S/N ratios of factor A, molecular weight of the polymer (range = 2.19, rank = 3), at two 
levels, suggested a directly proportional relationship with MW of polymer, i.e. the particle size 
decreases with a decrease in the MW of the polymer. This can also be evident from the lower 
particle size measurements observed using 14.7 KDa MW polymer (runs 1-9) relative to 24 
KDa MW polymer (runs 10-18). As the MW of polymer increases, the viscosity of the 
polymeric solution also increases, thereby imposing difficulty in breaking them into smaller 
emulsion droplets when compared to lower MW polymer requiring lower efficiency to 
breakdown under similar conditions. This increase in size of the particles has also been 
observed by others and is reported to be associated with high MW polymers [5,40,41] 
The S/N ratios of factor B, volume of organic solvent (DCM, range = 2.32, rank = 2), at three 
levels indicated that particle size almost linearly decreased with increase in volume from 1 to 
2 ml (S/N ratio, r2 = 0.999). This decrease in particle size is attributed to the  has been related 
to an increase in decrease in viscositiesy of the polymer solution (keeping the amount and MW 
of polymer constant). This makes it easier to break into smaller emulsion droplets resulting in 
a decreased particle size as explained above. This effect could also be observed with factor C, 
volume of 1st aqueous phase (range = 1.23, rank = 5), where a decrease in volume increased 
the viscosity thereby resulting in an increase in particle size. 
The S/N ratios for factor E, sonication time (range = 2.09, rank = 4), did not follow any 
particular trend; however, the 2nd level was found to be the optimum for achieving smaller 
particle size. The S/N ratios for parameters F, sonication timestirrer speed (the speed at which 
the magnetic bar was rotating for evaporation of DCM in the external phase) and G, 2nd PVA 
concentration have a low range of 0.34 and 0.18 respectively indicating that they have a 
minimal influence over the size of nanoparticles produced. Therefore, the optimum conditions 
inferred from the S/N response graph were A1B3C3D3E2F2G2 producing NPs of 128.50±6.57 
nm in size result in NPs of size suitable for cellular uptake into DC as established in the 
literature [16–18,42,43]. 
The adsorption of BSA onto NPs is expected to be mainly driven by hydrophobic, electrostatic 
(ionic) interactions and hydrogen bonding [44]. However, in this study as the NPs, evident 
from zeta-potential values, are negatively charged (-10.2±3.75 mV) and BSA in water is also 
highly negatively charged [45] suggesting that the electrostatic interactions are minimal and 
that the adsorption process is dominated by the hydrophobic interactions and hydrogen 
bonding. The BSA adsorption onto NPs increased with an increase in NP: BSA ratio from 100: 
4 to 100: 20, which was expected as the amount of BSA available for adsorption increased. 
Figure 2 (b) suggests that the surface of NPs was saturated with BSA after 1 h suggesting 
maximum adsorption with 100: 20 (NP: BSA) BSA loading concentration. 
4.2. Nanocomposite Microparticles Characterization 
NCMPs were produced by spray-drying using L-leucine as a carrier and a dispersibility 
enhancer. The SEM pictures (Fig. 3) show irregular or wrinkled surface which is due to an 
excessive build-up of vapour pressure during water evaporation in the spray drying process and 
occurs with hydrophobic amino acids, such as L-Leucine [8,46,47]. 
The release profile shows more than 90% of the BSA released within 48 h this is because of 
weaker hydrophobic interactions between BSA and NPs compared to the strong ionic 
interactions. Moreover, the identical bands observed for BSA standard and desorbed BSA from 
NCMPs suggests that protein has maintained its primary structure and was neither degraded 
nor affected by the adsorption and spray drying procedure. 
The secondary structure of BSA in the formulation was analysed using CD spectroscopy, a 
valuable technique in analysing the protein structure [32]. The BSA released samples confirms 
the presence of α-helix and β-sheets though decreased compared to standard BSA. However, 
in protein secondary structure, it is believed that the β-sheet structure is sometimes observed 
as a special α-helix only with two amino acid residues through stretching resulting from the 
breakage of hydrogen bond [37,48]. 
The FPF value (76.95±5.61 %) suggests an excellent aerosolization performance and deep lung 
deposition profile. The surface activity of the relatively strong hydrophobic alkyl side chain of 
L-leucine accumulating at the particle surface during spray drying reduces the surface free 
energy of the dry powder and cohesive inter-particulate interactions and this might be a 
plausible explanation for the enhanced dispersibility [8,24]. In addition, the dispersibility 
enhancing property of L-leucine resulting from its corrugated surface that reduces the contact 
points between particles leads to an improved aerosolization characteristic of powders 
[23,47,49]. Similar reports have also demonstrated the enhanced aerosol performance with L-
leucine containing formulations [23,47,49,50]. Moreover, the MMAD values show an efficient 
delivery of NCMPs containing BSA to the deep lungs mainly to the bronchial-alveolar region 
[3]. A study by Todoroff et al have shown that more intense specific immune responses could 
be achieved by targeting the antigen to the deep lungs than to the upper airways [51]. Also, 
Menzel et al have shown that upon inhalation of Pneumovax®, a pneumococcal polysaccharide 
vaccine, by healthy volunteers the vaccine deposited in the alveolar region displayed increased 
serum antibody levels compared to that deposited in the larger airways [52]. Thus, this 
deposition to the deep lungs may generate stronger immune responses. 
The NGI data (MMAD of 1.21±0.67 μm) suggests a deposition mainly in the bronchial-
alveolar region of the lungs[3], thus the cell viability studies were performed on A549 cell line 
(adenocarcinomic human alveolar basal epithelial cells) and 16HBE14o- cell line (human 
bronchial epithelial cells). The results show that both the cell lines were tolerant to the NCMPs 
up to 1.25 mg/ml concentration encouraging further investigation in animals. 
5. Conclusions 
PGA-co-PDL nanoparticles of appropriate size to target DCs were successfully produced using 
Taguchi L18 orthogonal array DoE. BSA adsorption onto NPs in the ratio of 100: 20 (NPs: 
BSA) for 1 h at room temperature produced the maximum adsorption of BSA (10.23±1.87 µg 
of protein per mg of NPs). The BSA adsorbed NPs were successfully spray-dried using L-
leucine into NCMPs producing a yield of 42.35±3.17% and the NCMPs had irregular and 
corrugated morphology. The BSA released from the NCMPs was shown to be maintaining its 
structure under SDS-PAGE and CD analysis. Moreover, FPF of 76.49±6.26 % and MMAD of 
1.21±0.67 μm values indicate deep lung deposition with NCMPs showing a low toxicity 
profile. This study suggests that PGA-co-PDL NCMPs could be used as a novel carrier for 
pulmonary vaccine delivery. 
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Table I Taguchi's Experimental Design L18 for producing PGA-co-PDL nanoparticles 
Levels Units 1 2 3 
A - MW of Polymer KDa 14.7 24.0 - 
B - Org Sol (DCM) ml 1 1.5 2 
C - Aq. Vol (PVA) ml 3 4 5 
D - 1st Aq. Conc (PVA) % w/v 2.5 5 10 
E - Sonication Time min 1 2 5 
F - Stirrer Speed RPM 400 500 600 
G - 2ndAq. Conc (PVA) % w/v 0.5 0.75 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table II Structure of Taguchi’s L18 orthogonal array, corresponding particle size and S/N ratios 
(Mean±SD, n=6) 
Runs 
Parameters 
Particle 
Size (nm) 
PDI 
S/N 
Ratio 
(dB) A B C D E F G 
Run 1 1 1 1 1 1 1 1 315.5±6.90 0.151±0.05 -49.979 
Run 2 1 1 2 2 2 2 2 186.5±4.30 0.097±0.03 -45.412 
Run 3 1 1 3 3 3 3 3 138.7±6.40 0.093±0.01 -42.843 
Run 4 1 2 1 1 2 2 3 210.1±18.7 0.116±0.04 -46.449 
Run 5 1 2 2 2 3 3 1 208.7±49.9 0.123±0.06 -46.389 
Run 6 1 2 3 3 1 1 2 182.0± 3.20 0.075±0.04 -45.199 
Run 7 1 3 1 2 1 3 2 192.9±9.30 0.077±0.04 -45.705 
Run 8 1 3 2 3 2 1 3 149.3±2.50 0.075±0.01 -43.481 
Run 9 1 3 3 1 3 2 1 192.9±23.0 0.050±0.03 -45.704 
Run 10 2 1 1 3 3 2 2 269.1±68.9 0.205±0.04 -48.598 
Run 11 2 1 2 1 1 3 3 459.4±69.5 0.233±0.02 -53.243 
Run 12 2 1 3 2 2 1 1 242.5±19.1 0.188±0.06 -47.694 
Run 13 2 2 1 2 3 1 3 253.2±47.3 0.155±0.10 -48.069 
Run 14 2 2 2 3 1 2 1 217.3±18.9 0.116±0.01 -46.742 
Run 15 2 2 3 1 2 3 2 240.5±35.1 0.133±0.05 -47.622 
Run 16 2 3 1 3 2 3 1 169.3±7.60 0.144±0.04 -44.573 
Run 17 2 3 2 1 3 1 2 235.9±29.6 0.119±0.08 -47.453 
Run 18 2 3 3 2 1 2 3 221.7±11.0 0.150±0.04 -46.915 
A - MW of Polymer, B - Org Sol (DCM), C - Aq. Vol (PVA), D - 1st Aq. conc (PVA), E - Sonication time, F - Stirrer Speed and G - 2nd Aq. 
conc (PVA) 
 
 
 
 
Table III Particle size and PDI of PGA-co-PDL nanoparticles without and with BSA 
adsorption 
 NP suspension Without BSA adsorption With  BSA adsorption 
Particle Size (nm) 128.50 ± 6.57a 203.9 ± 2.55b* 299.03 ± 32.02c* 
PDI 0.070 ± 0.030 0.205 ± 0.007 0.322 ± 0.060 
a NPs characterised immediately after preparation without centrifugation, b NPs characterised after centrifugation 
but without adsorption of BSA, c NPs characterised after centrifugation and BSA adsorption, * p < 0.05, 
ANOVA/Tukey’s comparison 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table IV The percentages of the secondary structures of standard, supernatant and released 
BSA samples 
Sample Helix Strand Turns Unordered 
     
Standard BSA 51 ± 0.007 21.1 ± 0.07 6.0 ± 0.01 18 ± 0.007 
     
Supernatant BSA 62.5 ± 0.035 22.0 ± 0.021 5.5 ± 0.05 9.5 ± 0.06 
     
Released BSA 36.0 ± 0 30.0  ± 0 7.0  ± 0 21  ± 0.007 
The content and level of secondary structure elements in the peptide was calculated from spectral data using the DichroWeb server software 
as described in Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legends to Figures 
Fig. 1 Mean S/N graph for particle size response. Letters (A–E) denote the experimental 
parameters and numeric values denote the parameter levels (  indicates maximum S/N value) 
(Mean±SD, n=6); Note: A - MW of Polymer, B - Org Sol (DCM), C - Aq. Vol (PVA), D - 1st Aq. conc (PVA), E - 
Sonication time, F - Stirrer Speed and G - 2nd Aq. conc (PVA) 
Fig. 2 Amount of BSA adsorbed per mg of NPs at different (a) BSA loading concentrations 
(NP: BSA) and (b) time points for 100: 20 (NP: BSA) BSA loading concentration, * is p < 0.5, 
** is p < 0.05, ANOVA/Tukey’s comparison (Mean±SD, n=3) 
Fig. 3 SEM pictures of PGA-co-PDL/L-Leu Nanocomposite Microparticles (a) 5 µm and (b) 
2 µm 
Fig. 4 Confocal microscopic image of spray-dried microparticles containing the fluorescent 
nanoparticles (red, labelled using nile red dye) adsorbed with FITC-BSA (green) (a) Split view 
and (b) Orthogonal view 
Fig. 5 In vitro release profiles for BSA adsorbed PGA-co-PDL/L-leu NCMPs in phosphate 
buffer saline, pH 7.4 (Mean±SD, n=3) 
Fig. 6 SDS-PAGE of Lane 1: molecular weight standards, broad range (Bio-Rad Laboratories, 
Hercules CA, USA), Lane 2, 3: BSA standards, Lane 4, 5, 6: Desorbed BSA from PGA-co-
PDL/L-leu NCMPs after 24 h 
Fig. 7 CD spectra of (a) standard BSA (grey) and supernatant BSA (black) and (b) standard 
BSA (grey) and BSA released (black) 
Fig. 8 A549 & 16HBE14o- cell viability measured by MTT assay after 24 h exposure to PGA-
co-PDL NCMPs (Mean±SD, n=3) 
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